The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Open accessAbstract
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) comprise the vast majority of EGFR mutations and are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi). However, low frequency mutations including point mutations, deletions, insertions and duplications occur within exons 18-25 of the EGFR gene in NSCLC and are associated with poorer responses to EGFRi. Despite an increased uptake of more sensitive detection methods to identify rare EGFR mutations in patients, our understanding of the biology of these rare EGFR mutations is poor compared to classical mutations. In particular, clinical data focused on these mutations is lacking due to their rarity and challenges in trial recruitment, resulting in an absence of effective treatment strategies for many low frequency EGFR mutations. In this review, we describe the structural and mechanistic features of rare EGFR mutations in NSCLC and discuss the preclinical and clinical evidence for EGFRi response for individual rare EGFR mutations. We also discuss EGFRi sensitivity for complex EGFR mutations, and conclude by offering a perspective on the outstanding questions and future steps required to make advances in the treatment of NSCLC patients that harbour rare EGFR mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter
Voon, P. J., Tsui, D. W. Y., Rosenfeld, N., & Chin, T. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0192 · Cited by 1,926
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Shi, Y., Au, J. S.-K., Thongprasert, S., Srinivasan, S., Tsai, C.-M., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G., & Yang, P.-C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,551
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 5×
“increased receptor dimerization and activity compared to WT [11,13,14].”
BackgroundResultInfluentialNovel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 738
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445
Sequist, L. V., Besse, B., Lynch, T. J., Miller, V. A., Wong, K. K., Gitlitz, B., Eaton, K., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 429
Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Self-citationTargeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Self-citationNatural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012) · Cell · doi:10.1016/j.cell.2012.02.063 · Cited by 357
Katakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., Ichinose, Y., Koboyashi, K., Takeda, K., Kiura, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0981 · Cited by 326
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Ono, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305
D'Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 301
Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000504 · Cited by 241
Eck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225
Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
Kobayashi, S., Canepa, H. M., Bailey, A. S., Nakayama, S., Yamaguchi, N., Goldstein, M. A., Huberman, M. S., & Costa, D. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182781e35 · Cited by 213
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203
Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn, M.-J., Sun, J.-M., Lee, S.-H., Ahn, J. S., & Park, K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300656 · Cited by 169
Ahn, M., Tsai, C., Shepherd, F. A., Bazhenova, L., Sequist, L. V., Hida, T., Yang, J. C. H., Ramalingam, S. S., Mitsudomi, T., Jänne, P. A., et al. (2019) · Cancer · doi:10.1002/cncr.31891 · Cited by 168
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 150
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
Schüler, M., Yang, J. C., Park, K., Kim, J., Bennouna, J., Chen, Y.-M., CHOUAID, C., de Marinis, F., Feng, J., Grossi, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv597 · Cited by 132
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131
Gallant, J., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0654 · Cited by 130
Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70461-9 · Cited by 127
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 122
Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
Yamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 110
Cheung, L. W. T., Yu, S., Zhang, D., Li, J., Ng, P. K., Panupinthu, N., Mitra, S., Ju, Z., Yu, Q., Liang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.08.017 · Cited by 105
Xu, J., Jin, B., Chu, T., Dong, X., Yang, H., Zhang, Y., Wu, D., Lou, Y., Zhang, X., Wang, H., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.018 · Cited by 92
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1206 · Cited by 88
Banno, E., Togashi, Y., Nakamura, Y., Chiba, M., Kobayashi, Y., Hayashi, H., Terashima, M., de Velasco, M. A., Sakai, K., Fujita, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12980 · Cited by 87
Baek, J. H., Sun, J., Min, Y. J., Cho, E. K., Cho, B. C., Kim, J.-H., Ahn, M., & Park, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.013 · Cited by 86
Takahashi, N., Hoshi, H., Higa, A., Hiyama, G., Tamura, H., Ogawa, M., Takagi, K., Goda, K., Okabe, N., Muto, S., et al. (2019) · Cells · doi:10.3390/cells8050481 · Cited by 80
Heigener, D. F., Schumann, C., Sebastian, M., Sadjadian, P., Stehle, I., Märten, A., Lüers, A., Griesinger, F., Scheffler, M., & for the Afatinib Compassionate Use Consortium (ACUC) (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0073 · Cited by 78
Cheng, G., Song, Z., & Chen, D. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s108242 · Cited by 77
S768I Mutation in EGFR in Patients with Lung Cancer
Leventakos, K., Kipp, B. R., Rumilla, K. M., Winters, J. L., Yi, E. S., & Mansfield, A. S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.007 · Cited by 74
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
Pines, G., Huang, P. H., Zwang, Y., White, F. M., & Yarden, Y. (2010) · Oncogene · doi:10.1038/onc.2010.313 · Cited by 71
Self-citationAsahina, H., Yamazaki, K., Kinoshita, I., Yokouchi, H., Dosaka-Akita, H., & Nishimura, M. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.005 · Cited by 63
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9007 · Cited by 61
Landau, M., & Ben‐Tal, N. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.08.001 · Cited by 58
Su, J., Zhong, W., Zhang, X., Huang, Y., Yan, H., Yang, J., Dong, Z., Xie, Z., Zhou, Q. H., Huang, X.-S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22768 · Cited by 56
Yang, M., Xu, X., Cai, J., Ning, J., Wery, J. P., & Li, Q. (2016) · International Journal of Cancer · doi:10.1002/ijc.30047 · Cited by 55
Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54
Masago, K., Fujita, S., Irisa, K., Kim, Y. H., Ichikawa, M., Mio, T., & Mishima, M. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq087 · Cited by 51
Peng, L., Song, Z.-G., & Jiao, S.-C. (2014) · Scientific Reports · doi:10.1038/srep06104 · Cited by 48
Kate, S., Chougule, A., Joshi, A., Noronha, V., Patil, V., Dusane, R., Solanki, L., Tiwrekar, P., Trivedi, V., & Prabhash, K. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s181406 · Cited by 48
Dominguez, C. L., Tsang, K.-Y., & Palena, C. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.297 · Cited by 47
Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
Wang, J., Li, X., Xue, X., Ou, Q., Wu, X., Liang, Y., Wang, X., You, M., Shao, Y. W., Zhang, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31895 · Cited by 45
Wu, J.-Y., & Shih, J.-Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118071 · Cited by 44
Baik, C. S., Wu, D., Smith, C., Martins, R. G., & Pritchard, C. C. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000586 · Cited by 42
Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
Loong, H. H.-F., Kwan, S.-C. S., Mok, T. S. K., & Lau, Y. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0570-9 · Cited by 41
Cheng, C., Wang, R., Li, Y., Pan, Y., Zhang, Y., Li, H., Zheng, D., Zheng, S., Shen, X., Sun, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep13959 · Cited by 38
Nivolumab in non-small-cell lung cancer with EGFR mutation
Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Yasuda, Y., Funazo, T. Y., & Hirai, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx745 · Cited by 35
Liu, Y., Wu, B., Zhong, H., Hui, P., & Fang, W. (2013) · Europe PMC (PubMed Central) · Cited by 34
Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
Harrison, P. T., & Huang, P. H. (2018) · Essays in Biochemistry · doi:10.1042/ebc20180016 · Cited by 32
Self-citationJang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation
Erdem‐Eraslan, L., Gao, Y., Kloosterhof, N. K., Atlasi, Y., Demmers, J., Sacchetti, A., Kros, J. M., Smitt, P. A. E. S., Aerts, J. G. J. V., & French, P. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.006 · Cited by 29
Gonzalvez, F., Zhu, X., Huang, W., Baker, T. E., Ning, Y., Wardwell, S., Nadworny, S., Zhang, S., Das, B., Gong, Y., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2644 · Cited by 29
Zhang, B., Wang, S., Qian, J., Yang, W., Qian, F., Lü, J., Zhang, Y., Qiao, R., & Han, B. (2018) · Cancer · doi:10.1002/cncr.31329 · Cited by 27
Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib
Hellmann, M. D., Reva, B. A., Yu, H. A., Rusch, V. W., Rizvi, N. A., Kris, M. G., & Arcila, M. E. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000221 · Cited by 26
Rare EGFR Exon 20 S768I Mutation Predicts Resistance to Targeted Therapy: A Report of Two Cases
Pallan, L., Taniere, P., & Koh, P. K. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000308 · Cited by 24
Ahn, M., Cho, J. H., Sun, J., Lee, S., Ahn, J. S., Park, K., Park, K. U., Kang, E. J., Choi, Y. H., Kim, K. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9050 · Cited by 23
Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment
Iyevleva, A. G., Mitiushkina, N. V., Karaseva, N. A., Орлов, С. В., Volodina, L. N., Kulikova, Y. E., Lozhkina, A. M., Ivantsov, A. O., Tiurin, V. I., Togo, A. V., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000106 · Cited by 17
Vyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 17
Self-citationTaniguchi, Y., Takeda, M., Tamiya, A., Kasai, T., & Atagi, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy401 · Cited by 9
Jangchul, P., Kondo, C., Shimizu, J., Horio, Y., Yoshida, K., & Hida, T. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a735cc · Cited by 8
Abstract 38: NSCLC patient-derived organoids to guide personalized therapy
Kim, S., Kim, D. H., Joo, H.-S., Yun, M. R., Lee, J. Y., Kim, S. M., Kim, H., Hong, M. H., Kim, H. R., & Cho, B. C. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-38 · Cited by 1
Cited by
Cho, B. C., Felip, E., Hayashi, H., Thomas, M., Lu, S., Besse, B., Sun, T., Martinez, M., Sethi, S. N., Shreeve, S. M., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0923 · Cited by 95
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
Peng, J., Yang, S., Ng, C. S. H., & Chen, G. G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108333 · Cited by 21
Metadata
- Authors
- Harrison, P. T., Vyse, S., & Huang, P. H.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 61
- Pages
- 167-179
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2976516489
- Cited by
- 615
- References
- 111
- FWCI
- 32.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.